Literature DB >> 14961986

Proinflammatory response of alveolar type II pneumocytes to in vitro hypoxia and reoxygenation.

Alexander S Farivar1, Steven M Woolley, Charles H Fraga, Karen Byrne, Michael S Mulligan.   

Abstract

Type II pneumocytes (T2P) are integral in preserving the integrity of the alveolar space by modulating the fluid composition surrounding the alveolar epithelium. There is also mounting evidence supporting their contribution to the development of acute inflammatory lung injury subsequent to oxidative stress. This study characterized the response of T2P to in vitro hypoxia and reoxygenation (H&amp;R). Rat T2P from a cultured cell line (RLE-6TN) were rendered hypoxic for 2 h, and reoxygenated for up to 6 h. Activation of signaling kinases, the nuclear translocation of proinflammatory transcription factors, and quantification of secreted cytokine and chemokine protein content were assessed. Type II pneumocytes expressed activated extracellular signal regulated kinase (ERK) 1/2 maximally at 15 min of reoxygenation. C-jun n-terminal kinase (JNK) and p38 activation was minimal at all time points studied. The nuclear translocation of nuclear factor kappa B (NFkappaB) and activator protein (AP)-1 were dramatic after 15 min of reoxygenation. There was a significant increase in the protein secretion of CINC (p = 0.03), IL-1beta (p = 0.02), and monocyte chemoattractant protein-1 (p < 0.001) at 6 h of reoxygenation. Type II pneumocytes respond directly to H&amp;R. ERK 1/2 activity peaks at 15 min of reoxygenation, and correlates temporally with the nuclear translocation of NFkappaB and AP-1. These signaling cascades likely promote the elaboration of proinflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961986     DOI: 10.1111/j.1600-6143.2004.00352.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  5 in total

1.  Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.

Authors:  Anton S McCourtie; Heather E Merry; Patrick S Wolf; Elizabeth FitzSullivan; John C Keech; Alexander S Farivar; Michael S Mulligan
Journal:  Ann Thorac Surg       Date:  2010-06       Impact factor: 4.330

2.  Lung injury after in vivo reperfusion: outcome at 27 hours after reperfusion.

Authors:  Idit Matot; Sharon Einav; Carolyn F Weiniger; Ron G Pearl; Rinat Abramovitch; Balachandra V Joshi; Kenneth A Jacobson
Journal:  Anesthesiology       Date:  2008-08       Impact factor: 7.892

3.  Alveolar macrophage secretory products effect type 2 pneumocytes undergoing hypoxia-reoxygenation.

Authors:  Anton S McCourtie; Alexander S Farivar; Steven M Woolley; Heather E Merry; Patrick S Wolf; Brendan Mackinnon-Patterson; John C Keech; Elizabeth Fitzsullivan; Michael S Mulligan
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

4.  A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion.

Authors:  Idit Matot; Carolyn F Weiniger; Evelyne Zeira; Eithan Galun; Bhalchandra V Joshi; Kenneth A Jacobson
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  Astragaloside IV attenuates hypoxia/reoxygenation injury-induced apoptosis of type II alveolar epithelial cells through miR-21-5p.

Authors:  Hang Li; Chang Yao; Kaihu Shi; Yang Zhao; Jin Du; Dinghui Hu; Zuntao Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.